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Introduction: Thymomas are rare neoplasms with variable clinical 
behavior. Our primary study aim was to analyze treatment practices 
and outcomes in a population-based cohort of thymoma patients. 
We hypothesized that stage I and II thymomas would have high cure 
rates with resection and adjuvant radiation, whereas locally advanced 
cases would benefit from multimodality therapy.
Methods: All patients, diagnosed with thymoma or thymic carci-
noma in British Columbia between 1994 and 2009, were identified 
using the British Columbia Cancer Agency Registry. Chart review 
was used to collect demographic and treatment data. Detailed pathol-
ogy review was performed using the World Health Organization 
classification.
Results: One hundred and seventy-one patients were identified 
for analysis. The 5-year overall survival was 93.3%, 88.7%, 74.6%, 
43.4% for stages I, II, III, and IV, respectively. Survival varied sig-
nificantly among patients with thymoma compared with thymic 
carcinoma. In patients with stage II disease, adjuvant radiation did 
not confer an overall survival or recurrence-free survival benefit. 
Seventy-five patients had locally advanced disease. There was prac-
tice variation in treatment of these patients. Patients with thymoma 
undergoing trimodality treatment had a 5-year median overall sur-
vival of 80%, whereas patients with thymic carcinoma had poor out-
comes despite aggressive treatment.
Conclusions: Survival rates in this population-based series were 
comparable to those in previously published reports. The ideal man-
agement of thymic tumors involves a multidisciplinary approach, 
particularly in locally advanced disease and selection of patients for 
adjuvant radiation therapy.
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Thymomas are rare tumors with an incidence of approxi-mately 0.15 cases per 100,000 person years.1 Unfortunately, 
little is known about the etiology of these malignancies2 and 
their clinical behavior can be quite variable. There has been 
widespread debate about their optimal classification. In 1995, 
the World Health Organization (WHO) proposed a new patho-
logic staging system that has since been widely accepted and 
has been proven to have prognostic value.3–5
The management of these tumors also continues to 
evolve. The role of surgery to treat localized disease has been 
well established.6 Adjuvant radiation has been used in selected 
cases, although its role remains controversial.7 In locally 
advanced and metastatic disease, a multimodality approach 
including chemotherapy, radiation therapy, and surgery has 
been used with some success,8–10 although the optimal regi-
men and sequencing of treatments is based on expert opinion 
from phase II trials rather than randomized comparisons of 
therapeutic strategies.
Although large series have helped elucidate the clinical 
behavior and optimal treatment regimens of these tumors, these 
data are based mainly on single-institution and surgical series. 
Population-based series have been largely epidemiologic and 
have not included detailed treatment and outcome data.11,12
The aim of this study was to detail a population-based 
series of all of the thymoma and thymic carcinoma cases in 
the province of British Columbia, to include demographic, 
clinical, pathologic, and treatment data based on the most up-
to-date reporting procedures. Before any data analyses, we 
hypothesized that stage I and II thymomas would have high 
cure rates with resection and adjuvant radiation, whereas 
locally advanced cases would benefit from multimodality 
therapy.
PATIENTS AND METHODS
Patient Selection
Approval for this retrospective chart review and 
pathology review was obtained from the BC Cancer Agency 
and University of British Columbia Research Ethics Board. 
All patients diagnosed with thymoma or thymic carcinoma 
between January 1, 1994 and December 31, 2008 in the entire 
province of British Columbia (population approximately 
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4.5 million) were identified using the British Columbia Cancer 
Agency (BCCA) Registry. Chart review was performed to 
collect demographic and treatment data. Disease-specific 
survival information was also collected from the BCCA 
Survival and Outcomes unit. Vital statistics were up to date as 
of December 2011.
Statistical Analysis
Descriptive statistics were used to summarize baseline 
characteristics of patients in the cohort. Survival curves were 
generated using the Kaplan–Meier method.
The methodology for reporting of outcomes and col-
lection of data was performed using criteria suggested by the 
International Thymic Malignancy Interest group (ITMIG). 
Given the long natural history of thymoma, the preferred out-
come for patients, who are treated with curative modalities 
with no residual disease, is freedom from recurrence, defined 
as the time from diagnosis to time to recurrence of thymic 
malignancy.13 We calculated this for all patients who had no 
visible disease remaining after curative treatment (either sur-
gery or radical radiotherapy).
Pathology and Staging Review
Stage was identified using the Masaoka–Koga system.14 
The pathologic diagnosis was retrieved from the original 
pathology report for cases reported using the WHO classifica-
tion of thymic tumor in 80 cases. A comprehensive pathology 
review and reclassification, using the WHO diagnostic criteria, 
was independently performed by two pathologists, one with 
expertise in thoracic pathology (DNI), for the remaining cases.
RESULTS
Identified Patients
Initially, 196 patients were identified. Five patients were 
excluded because of unconfirmed pathology, one patient was 
excluded because the date of diagnosis was before 1994. One 
hundred and seventy-one patients (90% of the provincial 
population) were referred to the BCCA and were available for 
analysis. Median follow-up time was 52 months.
Demographics and Clinical Presentation
Demographic data are summarized in Table 1. The 
median age at diagnosis was 59 years, with a range of 18 to 
84. Fifty percent of the patients were women. Thirty-one per-
cent of patients were asymptomatic at presentation, whereas 
20% presented with paraneoplastic syndromes. Other present-
ing symptoms included chest pain, cough, dyspnea, constitu-
tional symptoms, superior vena cava syndrome, effusions, and 
mass effect.
A variety of paraneoplastic phenomenon was observed 
(Table 1). Myasthenia gravis was present in 22% of the 
patients. Myasthenia gravis was seen more often in thymoma 
patients (23%, 34 of 147) than in thymic carcinoma patients 
(12%, 3 of 24). Other paraneoplastic phenonomena included 
pure red cell aplasia, hypogammaglobulinemia, hypercalce-
mia, motor axonal neuropathy, lympic encephalitis, and stiff-
person syndrome.
Stage at Presentation
As part of pathology review, the Masaoka–Koga stage 
was reviewed using 2011 guidelines published by the ITMIG.13 
A total of 16 patients’ stage was modified based on this review. 
Five patients were upstaged from stage IIb to stage III, based 
on slide review showing invasion into pleural or pericardial 
structures. Four patients were originally reported to have stage 
II disease because of incomplete capsule. The guidelines pro-
posed that these patients should be classified as having stage 
I disease. Other changes included one patient upstaged from 
I to II because of invasion into normal thymic tissue, and six 
patients whose stage was changed between IIa and IIb.
TABLE 1.  Demographics
n %
Age (yr)
18–30 9 5
31–40 8 5
41–50 31 18
51–60 38 22
61–70 45 26
71–80 33 19
>80 7 4
Sex
Male 86 50
Female 85 50
Presenting symptom
Asymptomatic 53 31
Paraneoplastic syndrome 35 20
Cough/dyspnea 34 20
Chest pain 29 17
Constitutional 6 4
SVC syndrome 4 2
Mass effect 4 2
Pericardial effusion 3 2
Pleural effusion 1 0.5
Hematuria 1 0.5
Thrombosis 1 0.5
Paraneoplastic phenomena
Myasthenia gravis 37 22
Pure red cell aplasia 3 1.8
Hypogammaglobulinemia 1
Hypercalcemia 1
Motor axonal neuropathy 1
Stiff-person syndrome 1
Limbic encephalitis 1
Syndrome of inappropriate  
ADH secretion
1
Stage at presentation
I 16 9
IIa 55 32
IIb 21 12
III 47 27
IVa 18 11
IVb 14 8
ADH, antidiuretic hormone; SVC, superior vena cava.
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The stage at presentation is described in Table 1. The 
stage distribution varied significantly with histology as outlined 
in Figure 1. The majority of patients with thymoma (WHO A, 
B, B1,B2,B3,AB) presented with early-stage disease, whereas 
nearly three-quarters of patients with thymic carcinoma pre-
sented with locally advanced or metastatic disease.
Survival by Stage
Survival by stage within the cohort was similar to that of 
previously published data (Fig. 2, Table 2). Five-year overall 
survival was 93.3%, 88.7%, 74.6%, and 43.4% for stages I, II, 
III, and IV, respectively. Ten-year overall survival was 93.3%, 
86.7%, 62%, and 28.9%.
Progression-free survival for 5 and 10 years was 92.3% 
and 92.3% for stage I, respectively, 84.4% and 72.9% for stage 
II, 55.1% and 39.2% for stage III, respectively. For stage IV 
patients, only a 5-year progression-free survival could be esti-
mated, which was 14.1%. Five-year freedom from recurrence 
was 100%, 92.8%, 68.0%, and 20.1% in patients with stage I, 
II, III, and IV, respectively (Table 2).
Survival by Histology
Sixty-seven patients had their WHO classification 
changed based on detailed pathological review. Twelve patients 
(7%) had WHO class A, 30 patients (17.5%) had WHO B1, 38 
patients (22%) had WHO B2, 27 patients (16%) had WHO B3 
17 patients (10%) had WHO AB, and 24 patients (14%) had 
thymic carcinoma. Thirteen percent of the patients were cat-
egorized as thymoma, but subtype analysis was not possible, 
when sample size was too small, or when original slides could 
not be obtained.
Survival varied significantly among patients with thy-
moma (WHO class A, B1, B2, B3, and AB) compared with 
thymic carcinoma as illustrated in Figure 5. Five-year overall 
survival in patients with thymoma was 82% compared with 
46% for thymic carcinoma.
Survival data was also calculated by WHO subtype 
(Table 3). Patients with WHO class A seemed to have a 
poorer survival compared with the other series15. These 
12 patients included two patients with disseminated disease 
at presentation, who did not receive any systemic therapy.
Management of Early-Stage Disease
Surgery
Our series included 13 patients with stage I disease. 
Twelve of these patients were treated with surgery alone, and 
one patient had adjuvant radiation for a positive resection 
margin. There were no tumor recurrences.
In patients with stage I and II disease (n = 92), surgery 
was most often a complete thymectomy (n = 57). Thirty-two 
patients had more extensive surgery, which involved resection 
of pericardium, lung tissue, and other surrounding structures. 
As illustrated in Table 4, more extensive surgery was associ-
ated with higher rates of R0 resection.FIGURE 1.  Stage and histology distribution.
FIGURE 2.  Overall survival by stage in all patients.
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FIGURE 3.  Progression-free survival by stage in all patients.
FIGURE 4.  Freedom from recurrence after curative treatment by stage.
TABLE 2.  Comparative Survival Rates 
Current Series Comparative Series
Stage N 5-yr OS 10-yr OS 5-yr PFS 10-yr PFS 5-yr FFR (n) Masoaka et al. 19  
5-yr OSa
Masaoka et al.19  
10-yr OS
De Jong et al. 11  
5- yr OSb
I 16 93.3% 93.3% 92.3% 92.3% 100 % (16) 96.2% 66.7% 82.9%
II 76 88.7% 86.7% 84.4% 72.9% 92.8 (76) 85.7% 60% 87.8%
III 47 74.6% 62.0% 55.1% 39.2% 68% (34) 69.6% 58.3% 57.6%
IV 32 43.4% 28.9% 14.1% (—) 20.1% (10) 50% 0% 55.6%
aOriginal data from Masaoka staging publication 
bPopulation-based study from The Netherlands.OS, overall survival; PFS, progression-free survival; FFR freedom from recurrence.
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Seventy percent of the surgeries were performed at a 
tertiary care center by a dedicated thoracic surgery team, per-
forming approximately 400 oncologic cases per year. Rates 
of R0 resection for thymoma at all stages were higher when 
surgery was performed at this center compared with periph-
eral centers.
Radiation
The use of radiation therapy in stage II disease was vari-
able. A total of 62% of patients with stage II disease received 
radiation therapy. In patients with positive margins (21 of 76), 
17 (81%) received adjuvant radiation. Similar proportions of 
stage IIa and stage IIb patients received radiation. The median 
dose was 50 Gy (range, 42–60), a three-field technique was 
used in more than 80% of patients. A total of six stage II 
patients (8%) had a recurrence. There was no difference 
observed in the overall survival or freedom from recurrence 
in stage II patients receiving and not receiving radiotherapy 
(Fig. 6).
Management of Advanced-Stage Disease
In a planned analysis, we specifically accessed out-
comes in locally advanced disease. This included all stage III 
and IVa patients and selected patients with stage IVb disease 
with local nodal involvement only. This accounted for a total 
of 75 patients, 67 of whom were offered curative treatment. 
There was considerable practice variation in the treatment of 
these patients, as illustrated in Figure 7. The dose of radia-
tion was similar to that used in the adjuvant setting (median 
50 Gy).
Approximately half of the patients received initial sur-
gery, whereas the other half received neoadjuvant therapy. 
In the group with upfront surgery, 31% of patients achieved 
an R0 resection. In the neoadjuvant group 14 patients (40%) 
underwent resection and 50% had an R0 resection. There was 
no difference in overall survival between the group treated 
neoadjuvantly and the group treated postoperatively.
In the locally advanced group, 17 patients received 
trimodality treatment including surgery, chemotherapy, and 
thoracic irradiation. Trimodality patients with thymoma 
had a 5-year median overall survival of 80%, whereas 
patients with thymic carcinoma had a 5-year median overall 
survival of 40% with no long-term survivors (Fig. 8). There 
was no statistical difference in overall survival between 
patients in the trimodality group and the rest of the locally 
advanced cohort.
Chemotherapy in Advanced Disease
Chemotherapy was used in 29% of the patients in our 
series. Cisplatin and etoposide constituted the initial regi-
men in 65% of patients. This choice was influenced by the 
ability to give this regimen concurrently with thoracic 
irradiation. Cyclophosphamide-cisplatin-doxorubacin +/− 
prednisone was used in 22% of the patients. Prednisone 
alone and octreotide were used occasionally in the palliative 
setting.
Recurrence
Follow-up practices were extremely variable for patient 
with both localized and advanced disease. A total of 23 
patients (17%) had recurrence after curative treatment. Six 
events occurred in stage II patients, 11 in stage III patients, 
and six in stage IV patients (Table 5). Among patients with 
stage II disease, five of six patients had a positive resection 
margin during the original surgery. Five of 23 recurring 
patients had thymic carcinoma. Recurrences were classified 
as local, regional, or distant, per ITMIG criteria. There were 
11 local recurrences to lung—nine regional recurrences and 
two distant recurrences. Time to recurrence ranged between 
55 days and 9.6 years, median 2.8 years.
Most patients received some form of treatment for recur-
rent disease. Modalities included surgery, radiation, and che-
motherapy. Ten patients died of thymic malignancy, including 
one who had a treatment-related death for febrile neutropenia.
FIGURE 5.  Overall survival by histology in all patients.
TABLE 3.  Relationship of Overall Survival with the 
WHOHistologic Subtype
WHO class n % 5-yr OS (%)
A 12 7 65.2
AB 17 10 100
B1 30 17 86.4
B2 38 22 82.5
B3 27 16 75.3
Thymic carcinoma 24 14 45.8
Thymoma, subtype not specified 23 13 (—)
WHO, World Health Organization; OS, overall survival.
TABLE 4.  Rate of R0 Resection in Patients with Stage I and II 
Disease by Surgery Type
Type Surgery Number of Patients
Rate of R0  
Resection, %
None 1 (—)
Partial thymectomy 2 50
Total thymectomy 57 68
Thymectomy + further resectiona 32 84
aIncluded patients receiving pericardectomy, wedge resection of lung, and 
innominate vein resection.
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FIGURE 6.  Freedom from recurrence in stage II patients treated with radiation.
FIGURE 7.  Initial management in patients with advanced stage disease. Xrt, radiation therapy; chemo, any chemotherapy; Rx, 
treatment.
Of the 13 patients alive at the time of analysis, three had 
repeat surgeries and have been followed for several years with-
out evidence of recurrent disease. This group also includes 
five patients with recurrent disease, who were not treated. 
Follow-up time in this group ranged between 6 months and 
6 years.
Prognostic Variables
We examined various pretreatment factors includ-
ing age, stage, paraneoplastic phenomenon, and histology 
for prognostic importance with respect to overall survival 
(Tables 6 and 7). In univariate analyses, advanced-stage thy-
mic carcinoma histology and nonmyasthenic paraneoplastic 
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phenomenae conferred a worse prognosis. In multivariate 
analysis, only stage and histology (thymoma versus thymic 
carcinoma) were statistically significant.
Second Malignancy
Several studies have highlighted a possible link between 
thymoma and secondary malignancies.1, 2, 16, 17 Our review 
allowed capture of extrathymic malignancies diagnosed dur-
ing the study period. A total of 19 patients (11%) were diag-
nosed with nonthymic malignancies (excluding basal cell 
carcinoma of the skin) during study and follow-up period. 
Nine patients had been previously diagnosed with malig-
nancy: one seminoma, one renal cell cancer, one prostate 
cancer, one esophageal cancer, one Hodgkin’s lymphoma, two 
breast cancers, one non–small-cell lung cancer, and two low-
grade non-Hodgkin’s lymphomas. An additional three patients 
were diagnosed with non–small-cell lung cancer, and one with 
aggressive non-Hodgkin’s lymphoma at the time of thymoma 
diagnosis. In follow-up, seven patients were diagnosed with 
malignancies:two non–small-cell lung cancers, one renal cell, 
one breast, one melanoma, and two head and neck cancers.
DISCUSSION
This series represents one of the largest and most 
complete population-based reports of thymoma and thymic 
carcinoma. In this unselected population, our outcomes for 
thymoma based on stage were similar to that of other large, 
reported, institutional series.11, 18, 19 Our series highlights the 
variability in clinical behavior and practice variations within 
the province of British Columbia.
Our study was limited by the retrospective nature of our 
data. Furthermore, a small percentage of the patients’ data 
(10%) was not available for analysis. This probably explains 
the relatively low number of stage I patients in our cohort as 
these patients are often not referred to the BCCA for further 
oncologic assessment after primary curative surgical therapy. 
Our median follow-up time was 5 years, and a longer follow-up 
may have provided more data about long-term recurrences. 
The reality of late recurrences underscores the importance of 
long-term follow-up for patients with thymoma. Our review 
also highlights the need for detailed pathology and staging 
review for these rare tumors.
In early-stage disease, similar to previously published 
data, more extensive surgery was performed at a high-
volume center to achieve R0 resection improved outcomes. 
FIGURE 8.  Outcomes in patients treated with surgery, radiation therapy, and chemotherapy.
TABLE 5.  Recurrences by Stage in Patients Receiving 
Curative Treatment
Stage n Number of Recurrences %
II 76 6 8
III 34 11 32
IV 10 6 60
TABLE 6.  Univariate Analysis of Prognostic Factors
Variable Comparison Hazard Ratio p
Stage I vs. IV 0.1181 0.0041
Stage II vs. IV 0.1144 0.0000
Stage III vs. IV 0.3717 0.0043
Paraneoplastic Myasthenia vs. non-
Myasthenia syndromes
0.2608 0.0378
Paraneoplastic None vs. non-Myasthenia 
syndromes
0.4930 0.1813
Histotype Thymoma vs. thymic 
carcinoma
0.2021 0.0000
Age (yr) <50 vs. > =50 0.7866 0.5033
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In our series, selected patients were offered postoperative 
radiation therapy. Although this series was unable to 
demonstrate a clear-cut benefit from radiation, several larger 
series have supported its use.20–22 The long clinical course of 
this disease requires careful selection for radiotherapy, 
given its potential for late toxicity including coronary artery 
disease, thyroid dysfunction, and secondary malignancies.23 
A more detailed pathological review of patients with stage 
II disease is currently underway to see whether size, margin 
status, and histologic characteristics may be able to predict 
which patient may benefit from a more aggressive local 
therapy.
Our data support a multidisciplinary team approach for 
management of these patients, similar to previously published 
reports.9, 24–26 In particular, patients with thymoma had 
excellent results using a trimodality approach. Preoperative 
chemoradiation has the potential for better preoperative 
downstaging as has been observed in the treatment of locally 
advanced lung cancer.27 More effective downstaging may 
diminish the chance of drop metastases at the time of surgery. 
Preoperative chemoradiation for thymic tumors should not be 
associated with problematic high rates of operative mortality 
as has been reported in lung cancer because there is little or 
no resection of lung tissue itself in thymoma surgeries. The 
patient disposition should be made in a multidisciplinary 
conference including thoracic surgery, radiation oncology, 
medical oncology, pathology, and radiology. The treatment 
plan should be delineated at the time of diagnosis before 
initiation of any modality.
Unfortunately, patients with thymic carcinoma had 
poor outcomes despite aggressive treatment. Innovative 
new therapy is clearly needed to improve results for these 
patients.
We reported a 17% recurrence rate after curative treat-
ment. Because most recurrences are local and potentially 
treatable, this again argues for long-term follow-up for these 
patients. To date, there are no established guidelines for rou-
tine follow-up imaging after thymoma resection.
In summary we present a detailed population- 
based series that highlights the many challenges clinicians 
face when treating thymic malignancies, where evidence-
based therapy information is limited. Although advances in 
surgical techniques, radiation planning, systemic therapy, 
and supportive care have been used in the care of patients 
with thymic malignancies, more research and collaborative 
efforts are needed to produce evidence-based guidelines. 
International database projects and multidisplinary meetings 
supported by the ITMIG will undoubtedly help fulfil this 
need.28
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